Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients

ABSTRACT Background: Vitiligo is a depigmenting disorder characterized by the appearance of circumscribed white macules in the skin. The aetiology of vitiligo is not clear, and although various hypotheses have been proposed. It has been suggested that autoimmunity plays an important role in the pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	radwa abd El-Halim, Hasan Mohamed, Ibrahim Fouda, Hesham Abd El-Samee
Formato:	article
Lenguaje:	EN
Publicado:	Al-Azhar University, Faculty of Medicine (Damietta) 2019
Materias:	vitiligo sb100 psoralen ultraviolet disease severity Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/eb91b95853ac4ee6acf50fd2137a1901
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb91b95853ac4ee6acf50fd2137a1901
record_format	dspace
spelling	oai:doaj.org-article:eb91b95853ac4ee6acf50fd2137a19012021-12-02T15:22:19ZEvaluation of S100B serum level as a biomarker of disease activity in vitiligo patients2636-41742682-378010.21608/ijma.2019.12021.1001https://doaj.org/article/eb91b95853ac4ee6acf50fd2137a19012019-07-01T00:00:00Zhttps://ijma.journals.ekb.eg/article_33976_70d351c321a70a8ba9c1c39d4c9594e9.pdfhttps://doaj.org/toc/2636-4174https://doaj.org/toc/2682-3780ABSTRACT Background: Vitiligo is a depigmenting disorder characterized by the appearance of circumscribed white macules in the skin. The aetiology of vitiligo is not clear, and although various hypotheses have been proposed. It has been suggested that autoimmunity plays an important role in the pathogenesis of vitiligo. Objective: To evaluate the serum levels of S100B as it could be used as biomarker of disease activity in vitiligo patients. Patients and Methods: The current study included 45 patients with vitiligo and 45 healthy controls. Patients were divided into two groups, segmental vitiligo (group I) including 4 patients and generalized vitiligo (group II) including 41 patients. All participants were recruited from the outpatient clinic of Al-Azhar University hospital (Damietta) and Dermatology, Venereology, Leprosy in June 2018. Results: S100B serum levels were high in patients with vitiligo as compared to the control subjects. S100B were significantly higher in non segmental vitiligo. S100B serum levels were higher in active vitiligo patients as compared to inactive vitiligo patients. There was no significant difference between the studied groups regarding age, gender, duration of the disease and Fitzpatrick skin phototype. Conclusion: Vitiligo patients have been associated with high levels of S100B, indicating its possible involvement in its pathogenesis. Levels of S100B may be a potential target for treatment. It is needed to perform further studies with larger sample size including patients and controls and follow up monitoring of activity in needed to evaluate of S100B.radwa abd El-HalimHasan MohamedIbrahim FoudaHesham Abd El-SameeAl-Azhar University, Faculty of Medicine (Damietta)articlevitiligosb100psoralenultravioletdisease severityMedicine (General)R5-920ENInternational Journal of Medical Arts, Vol 1, Iss 1, Pp 37-41 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	vitiligo sb100 psoralen ultraviolet disease severity Medicine (General) R5-920
spellingShingle	vitiligo sb100 psoralen ultraviolet disease severity Medicine (General) R5-920 radwa abd El-Halim Hasan Mohamed Ibrahim Fouda Hesham Abd El-Samee Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients
description	ABSTRACT Background: Vitiligo is a depigmenting disorder characterized by the appearance of circumscribed white macules in the skin. The aetiology of vitiligo is not clear, and although various hypotheses have been proposed. It has been suggested that autoimmunity plays an important role in the pathogenesis of vitiligo. Objective: To evaluate the serum levels of S100B as it could be used as biomarker of disease activity in vitiligo patients. Patients and Methods: The current study included 45 patients with vitiligo and 45 healthy controls. Patients were divided into two groups, segmental vitiligo (group I) including 4 patients and generalized vitiligo (group II) including 41 patients. All participants were recruited from the outpatient clinic of Al-Azhar University hospital (Damietta) and Dermatology, Venereology, Leprosy in June 2018. Results: S100B serum levels were high in patients with vitiligo as compared to the control subjects. S100B were significantly higher in non segmental vitiligo. S100B serum levels were higher in active vitiligo patients as compared to inactive vitiligo patients. There was no significant difference between the studied groups regarding age, gender, duration of the disease and Fitzpatrick skin phototype. Conclusion: Vitiligo patients have been associated with high levels of S100B, indicating its possible involvement in its pathogenesis. Levels of S100B may be a potential target for treatment. It is needed to perform further studies with larger sample size including patients and controls and follow up monitoring of activity in needed to evaluate of S100B.
format	article
author	radwa abd El-Halim Hasan Mohamed Ibrahim Fouda Hesham Abd El-Samee
author_facet	radwa abd El-Halim Hasan Mohamed Ibrahim Fouda Hesham Abd El-Samee
author_sort	radwa abd El-Halim
title	Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients
title_short	Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients
title_full	Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients
title_fullStr	Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients
title_full_unstemmed	Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients
title_sort	evaluation of s100b serum level as a biomarker of disease activity in vitiligo patients
publisher	Al-Azhar University, Faculty of Medicine (Damietta)
publishDate	2019
url	https://doaj.org/article/eb91b95853ac4ee6acf50fd2137a1901
work_keys_str_mv	AT radwaabdelhalim evaluationofs100bserumlevelasabiomarkerofdiseaseactivityinvitiligopatients AT hasanmohamed evaluationofs100bserumlevelasabiomarkerofdiseaseactivityinvitiligopatients AT ibrahimfouda evaluationofs100bserumlevelasabiomarkerofdiseaseactivityinvitiligopatients AT heshamabdelsamee evaluationofs100bserumlevelasabiomarkerofdiseaseactivityinvitiligopatients
_version_	1718387425002127360

Evaluation of S100B serum level as a biomarker of disease activity in vitiligo patients

Ejemplares similares